[ITOC 2017] Phenotypic Human Primary Cell-Based Tumor Microenvironment Models for Evaluation of Drug Combination for Immune Oncology

[ITOC 2017] Phenotypic Human Primary Cell-Based Tumor Microenvironment Models for Evaluation of Drug Combination for Immune Oncology
Version:
20731

File Name/Number:
2017 ITOC

Year:
2017

We evaluated multiple oncology drugs, including pembrolizumab (α-PD-1) and paclitaxel (anti-mitotic) alone and in combination, across the broad non-cancer Diversity PLUS panel and in the oncology systems.